Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 56Triple Negative Breast Neoplasms 14Sarcoma 7Neoplasm Metastasis 6Neoplasms 3HER2-negative Breast Cancer 3Carcinoma, Non-Small-Cell Lung 3Urethral Neoplasms 2Ureteral Neoplasms 2Prostatic Neoplasms 2Inflammatory Breast Neoplasms 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Liposarcoma 1Leiomyosarcoma 1Ketosis 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1

Interventions

Paclitaxel 56Carboplatin 56Bevacizumab 43Gemcitabine 20Taxes 19pembrolizumab 15Immunoglobulin G 13Disulfides 13Topotecan 12olaparib 11Cisplatin 11niraparib 9Cyclophosphamide 9liposomal doxorubicin 8Specimen Handling 7Docetaxel 6Biopsy 6mirvetuximab soravtansine 5Nivolumab 5Magnetic Resonance Spectroscopy 5Letrozole 5Hyperthermic Intraperitoneal Chemotherapy 5Drug Therapy 5Cytoreduction Surgical Procedures 5Albumin-Bound Paclitaxel 5rucaparib 4pazopanib 4oregovomab 4Surgical Procedures, Operative 4Neoadjuvant Therapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Fallopian Tube Neoplasms × eribulin × Clear all
NCT00334893 2017-11-29

Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 2 Completed
74 enrolled 7 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡